US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

24.43

-2.5400-9.42%

Post-market: 24.900.4700+1.92%17:06 EDT

Volume:79.82K

Turnover:1.98M

Market Cap:274.14M

PE:-3.12

High:26.39

Open:25.00

Low:24.00

Close:26.97

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Palvella Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

125 Strafford Avenue,Suite 360,Wayne,Pennsylvania,United States

Website:

http://www.pieris.com

Zip Code:

19087

Phone:

Fax:

- -

Introduction:

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Directors

Name

Position

James Geraghty

Director and Chairman

Stephen S. Yoder

Director,Chief Executive Officer and President

Ann Barbier

Director

Christopher Kiritsy

Director

Jean Pierre Bizzari

Director

Michael Richman

Director

Steven Prelack

Director

Shareholders

Name

Position

Stephen S. Yoder

Director,Chief Executive Officer and President

Allan Reine

Senior Vice President, Chief Financial Officer and Treasurer

Louis A. Matis

Senior Vice President and Chief Development Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":24.43,"timestamp":1743710400000,"preClose":26.97,"halted":0,"volume":79818,"hourTrading":{"tag":"盘后","latestPrice":24.9,"preClose":24.43,"latestTime":"17:06 EDT","volume":3,"amount":73.759998,"timestamp":1743714382387},"delay":0,"floatShares":6497315,"shares":11221307,"eps":-7.832217,"marketStatus":"Post-Market Trading","change":-2.54,"latestTime":"04-03 19:20:05 EDT","open":25,"high":26.39,"low":24,"amount":1981834.485924,"amplitude":0.088617,"askPrice":28.6,"askSize":100,"bidPrice":22,"bidSize":975,"shortable":0,"etf":0,"ttmEps":-7.832217,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743724800000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":26.97,"preHourTrading":{"tag":"盘前","latestPrice":25.59,"preClose":26.97,"latestTime":"09:27 EDT","volume":806,"amount":20702.959523999998,"timestamp":1743686828388},"postHourTrading":{"tag":"盘后","latestPrice":24.9,"preClose":24.43,"latestTime":"17:06 EDT","volume":3,"amount":73.759998,"timestamp":1743714382387},"volumeRatio":1.043206,"impliedVol":0.4687,"impliedVolPercentile":0.5217},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6497315,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":1.043206,"shares":11221307,"dividePrice":0,"high":26.39,"amplitude":0.088617,"preClose":26.97,"low":24,"week52Low":6.2,"pbRate":"4.38","week52High":29.27,"institutionHeld":0,"latestPrice":24.43,"committee":0.813953,"eps":-7.832217,"divideRate":0,"volume":79818,"delay":0,"ttmEps":-7.832217,"open":25,"prevYearClose":12,"prevWeekClose":28.1,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":27.76,"twentyDayClose":23.94,"sixtyDayClose":14.755},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":534271315,"address":"125 Strafford Avenue,Suite 360,Wayne,Pennsylvania,United States","zipCode":"19087","officePhone":"484 253 1461"},"stockCompanyDetail":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.3795},{"period":"3month","weight":1.2475},{"period":"6month","weight":0.6587},{"period":"1year","weight":0.894},{"period":"ytd","weight":1.2475}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":-0.033},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.0148},{"period":"1year","weight":0.088},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.102904},{"month":2,"riseRate":0.5,"avgChangeRate":0.02179},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.072506},{"month":5,"riseRate":0.555556,"avgChangeRate":0.187589},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.091514},{"month":7,"riseRate":0.7,"avgChangeRate":0.124373},{"month":8,"riseRate":0.6,"avgChangeRate":0.081761},{"month":9,"riseRate":0.3,"avgChangeRate":-0.115283},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082714},{"month":11,"riseRate":0.5,"avgChangeRate":0.04477},{"month":12,"riseRate":0.3,"avgChangeRate":-0.058257}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":{"directors":[{"name":"James Geraghty","position":"Director and Chairman"},{"name":"Stephen S. Yoder","position":"Director,Chief Executive Officer and President"},{"name":"Ann Barbier","position":"Director"},{"name":"Christopher Kiritsy","position":"Director"},{"name":"Jean Pierre Bizzari","position":"Director"},{"name":"Michael Richman","position":"Director"},{"name":"Steven Prelack","position":"Director"}],"executives":[{"name":"Stephen S. Yoder","position":"Director,Chief Executive Officer and President"},{"name":"Allan Reine","position":"Senior Vice President, Chief Financial Officer and Treasurer"},{"name":"Louis A. Matis","position":"Senior Vice President and Chief Development Officer"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1742961600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-02","current":-15.183586,"percent":0,"low":-15.183586,"twenty":20.817306,"median":28.371332,"eighty":43.469842,"high":46.119317,"avg":29.385721,"sd":10.926182,"marketCap":264710632},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-02","current":-15.183586,"twenty":20.817306,"median":28.371332,"eighty":43.469842,"marketCap":264710632}],"updateTime":1743706407885}}}